The protective effect and mechanism of the FXR agonist obeticholic acid via targeting gut microbiota in non-alcoholic fatty liver disease

References

• Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015;313:2263–2273. doi:10.1001/jama.2015.537026057287
   PubMed Web of Science ®Google Scholar
• Wruck W, Graffmann N, Kawala MA, Adjaye J. Concise review: current status and future directions on research related to nonalcoholic fatty liver disease. Stem Cells. 2017;35:89–96. doi:10.1002/stem.245427374784
   PubMed Web of Science ®Google Scholar
• Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science. 2011;332:1519–1523. doi:10.1126/science.120426521700865
   PubMed Web of Science ®Google Scholar
• Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012;142:1592–1609. doi:10.1053/j.gastro.2012.04.00122656328
   PubMed Web of Science ®Google Scholar
• Han CY. Update on FXR biology: promising therapeutic target? Int J Mol Sci. 2018;19:2069. doi:10.3390/ijms19072069
   PubMed Web of Science ®Google Scholar
• Chavez-Talavera O, Tailleux A, Lefebvre P, Staels B. Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia, and nonalcoholic fatty liver disease. Gastroenterology. 2017;152:1679–1694. doi:10.1053/j.gastro.2017.01.05528214524
   PubMed Web of Science ®Google Scholar
• Morrison MC, Verschuren L, Salic K, et al. Obeticholic acid modulates serum metabolites and gene signatures characteristic of human NASH and attenuates inflammation and fibrosis progression in ldlr-/-.leiden mice. Hepatol Commun. 2018;2:1513–1532. doi:10.1002/hep4.127030556039
   PubMed Web of Science ®Google Scholar
• Kakiyama G, Pandak WM, Gillevet PM, et al. Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. J Hepatol. 2013;58:949–955. doi:10.1016/j.jhep.2013.01.00323333527
   PubMed Web of Science ®Google Scholar
• Hooper LV, Gordon JI. Commensal host-bacterial relationships in the gut. Science. 2001;292:1115–1118.11352068
   PubMed Web of Science ®Google Scholar
• Kau AL, Ahern PP, Griffin NW, Goodman AL, Gordon JI. Human nutrition, the gut microbiome and the immune system. Nature. 2011;474:327–336. doi:10.1038/nature1021321677749
   PubMed Web of Science ®Google Scholar
• Tremaroli V, Backhed F. Functional interactions between the gut microbiota and host metabolism. Nature. 2012;489:242–249. doi:10.1038/nature1155222972297
   PubMed Web of Science ®Google Scholar
• Bakhtiar SM, LeBlanc JG, Salvucci E, et al. Implications of the human microbiome in inflammatory bowel diseases. FEMS Microbiol Lett. 2013;342:10–17. doi:10.1111/1574-6968.1211123431991
   PubMed Web of Science ®Google Scholar
• Vijay-Kumar M, Aitken JD, Carvalho FA, et al. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science. 2010;328:228–231. doi:10.1126/science.117972120203013
   PubMed Web of Science ®Google Scholar
• Nicholson JK, Holmes E, Kinross J, et al. Host-gut microbiota metabolic interactions. Science. 2012;336:1262–1267. doi:10.1126/science.122381322674330
   PubMed Web of Science ®Google Scholar
• Perry RJ, Peng L, Barry NA, et al. Acetate mediates a microbiome-brain-beta-cell axis to promote metabolic syndrome. Nature. 2016;534:213–217. doi:10.1038/nature1830927279214
   PubMed Web of Science ®Google Scholar
• Liu HN, Wu H, Chen YZ, Chen Y-J, Shen X-Z, Liu -T-T. Altered molecular signature of intestinal microbiota in irritable bowel syndrome patients compared with healthy controls: a systematic review and meta-analysis. Dig Liver Dis. 2017;49:331–337. doi:10.1016/j.dld.2017.01.14228179092
   PubMedGoogle Scholar
• Chen YJ, Wu H, Wu SD, et al. Parasutterella, in association with irritable bowel syndrome and intestinal chronic inflammation. J Gastroenterol Hepatol. 2018;33:1844–1852. doi:10.1111/jgh.1428129744928
   PubMed Web of Science ®Google Scholar
• Xie G, Wang Y, Wang X, et al. Profiling of serum bile acids in a healthy Chinese population using UPLC-MS/MS. J Proteome Res. 2015;14:850–859. doi:10.1021/pr500920q25581415
   PubMed Web of Science ®Google Scholar
• Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62:S47–S64.25920090
   PubMed Web of Science ®Google Scholar
• Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology. 2010;52:1836–1846. doi:10.1002/hep.2400121038418
   PubMed Web of Science ®Google Scholar
• Zafrani ES. Non-alcoholic fatty liver disease: an emerging pathological spectrum. Virchows Arch. 2004;444:3–12. doi:10.1007/s00428-003-0943-714685853
   PubMed Web of Science ®Google Scholar
• Fuchs M. Non-alcoholic Fatty liver disease: the bile Acid-activated farnesoid x receptor as an emerging treatment target. J Lipids. 2012;2012:934396. doi:10.1155/2012/93439622187656
   PubMedGoogle Scholar
• Manley S, Ding W. Role of farnesoid X receptor and bile acids in alcoholic liver disease. Acta Pharm Sin B. 2015;5:158–167. doi:10.1016/j.apsb.2014.12.01126579442
   PubMed Web of Science ®Google Scholar
• Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015;385:956–965. doi:10.1016/S0140-6736(14)61933-425468160
   PubMed Web of Science ®Google Scholar
• Cipriani S, Mencarelli A, Palladino G, Fiorucci S. FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. J Lipid Res. 2010;51:771–784. doi:10.1194/jlr.M00160219783811
   PubMed Web of Science ®Google Scholar
• Fickert P, Fuchsbichler A, Moustafa T, et al. Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts. Am J Pathol. 2009;175:2392–2405. doi:10.2353/ajpath.2009.09011419910507
   PubMed Web of Science ®Google Scholar
• Verbeke L, Farre R, Trebicka J, et al. Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. Hepatology. 2014;59:2286–2298. doi:10.1002/hep.2693924259407
   PubMed Web of Science ®Google Scholar
• Armstrong MJ, Newsome PN. Trials of obeticholic acid for non-alcoholic steatohepatitis. Lancet. 2015;386:28.
   PubMed Web of Science ®Google Scholar
• Mao Y, Zhou C, Zhu L, et al. Identification and expression analysis on bactericidal permeability-increasing protein (BPI)/lipopolysaccharide-binding protein (LBP) of ark shell, Scapharca broughtonii. Fish Shellfish Immunol. 2013;35:642–652. doi:10.1016/j.fsi.2013.05.02523742867
   PubMed Web of Science ®Google Scholar
• Cani PD, Bibiloni R, Knauf C, et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes. 2008;57:1470–1481. doi:10.2337/db07-140318305141
   PubMed Web of Science ®Google Scholar
• Pendyala S, Walker JM, Holt PR. A high-fat diet is associated with endotoxemia that originates from the gut. Gastroenterology. 2012;142:1100–1101. doi:10.1053/j.gastro.2012.01.03422326433
   PubMed Web of Science ®Google Scholar
• Ruiz AG, Casafont F, Crespo J, et al. Lipopolysaccharide-binding protein plasma levels and liver TNF-alpha gene expression in obese patients: evidence for the potential role of endotoxin in the pathogenesis of non-alcoholic steatohepatitis. Obes Surg. 2007;17:1374–1380. doi:10.1007/s11695-007-9243-718000721
   PubMed Web of Science ®Google Scholar
• Sakura T, Morioka T, Shioi A, et al. Lipopolysaccharide-binding protein is associated with arterial stiffness in patients with type 2 diabetes: a cross-sectional study. Cardiovasc Diabetol. 2017;16:62. doi:10.1186/s12933-017-0624-528486964
   PubMed Web of Science ®Google Scholar
• Luo Y, Liu M. Adiponectin: a versatile player of innate immunity. J Mol Cell Biol. 2016;8:120–128. doi:10.1093/jmcb/mjw01226993045
   PubMed Web of Science ®Google Scholar
• Sayin SI, Wahlstrom A, Felin J, et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab. 2013;17:225–235. doi:10.1016/j.cmet.2013.01.00323395169
   PubMed Web of Science ®Google Scholar
• Jenq RR, Taur Y, Devlin SM, et al. Intestinal Blautia is associated with reduced death from graft-versus-host disease. Biol Blood Marrow Transplant. 2015;21:1373–1383. doi:10.1016/j.bbmt.2015.04.01625977230
   PubMed Web of Science ®Google Scholar
• Byrne CS, Chambers ES, Morrison DJ, Frost G. The role of short chain fatty acids in appetite regulation and energy homeostasis. Int J Obes (Lond). 2015;39:1331–1338. doi:10.1038/ijo.2015.8425971927
   PubMed Web of Science ®Google Scholar
• Rios-Covian D, Ruas-Madiedo P, Margolles A, et al. Intestinal short chain fatty acids and their link with diet and human health. Front Microbiol. 2016;7:185. doi:10.3389/fmicb.2016.0018526925050
   PubMed Web of Science ®Google Scholar
• Hooper LV, Littman DR, Macpherson AJ. Interactions between the microbiota and the immune system. Science. 2012;336:1268–1273. doi:10.1126/science.122349022674334
   PubMed Web of Science ®Google Scholar
• Maynard CL, Elson CO, Hatton RD, Weaver CT. Reciprocal interactions of the intestinal microbiota and immune system. Nature. 2012;489:231–241. doi:10.1038/nature1155122972296
   PubMed Web of Science ®Google Scholar
• Koh A, De Vadder F, Kovatcheva-Datchary P, Bäckhed F. From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites. Cell. 2016;165:1332–1345. doi:10.1016/j.cell.2016.05.04127259147
   PubMed Web of Science ®Google Scholar
• Dupont J, Oh SY, O’Deen LA, Geller S. Cholanoic (bile) acids in hepatic and nonhepatic tissues of miniature swine. Lipids. 1974;9:294–297.4833441
   PubMed Web of Science ®Google Scholar
• Inagaki T, Choi M, Moschetta A, et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab. 2005;2:217–225. doi:10.1016/j.cmet.2005.09.00116213224
   PubMed Web of Science ®Google Scholar